CymaBay Therapeutics Inc. is scrapping two mid-stage trials of the liver disease drug seladelpar after biopsies found a type of liver damage in some patients, sending the company’s shares down more than 75 percent.
Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.
Thrive Earlier Detection Corp., a liquid biopsy company, raised $110 million in Series A funding.
Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy
Advanced Non-Small Cell Lung Cancer, Assays, Biomarkers, Business, Clinical Trials, Collaborations, Gene Expression, Genomes, Liquid Biopsies, Oncology, Tumor Biopsies, TumorsPersonal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).